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Background: In previous papers, we found significantly higher activity of chitotriosidase, a
macrophage derived enzyme, in serum and BAL of patients with sarcoidosis, especially in
those with progressing disease and lung involvement, than in controls. Locally and
systemically produced chitotriosidase activity was correlated with radiological stage and
also with degree of lung infiltration, suggesting that this enzyme may play a role in the
pathogenesis of sarcoidosis and may be used as a marker of disease severity.
Aim: To analyse chitotriosidase activity in serum and bronchoalveolar lavage of patients
with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with systemic sclerosis
and to compare it with chitotriosidase activity in controls and sarcoidosis patients.
Methods: Chitotriosidase activity was determined by a fluorometric assay.
Results: The results showed that serum chitotriosidase activity was only elevated in sarcoidosis
patients; in patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with
systemic sclerosis it was in the normal range. On the contrary, in BAL of sarcoidosis and
idiopathic pulmonary fibrosis patients the activity was significantly higher than in controls.
Conclusion: Serum chitotriosidase is a potential marker of sarcoidosis severity; it increases in
sarcoidosis in relation to radiological stage and degree of lung infiltration. The increase in
chitotriosidase activity in BAL of sarcoidosis and idiopathic pulmonary fibrosis patients suggests
that the enzyme could be involved in fibrogenesis in diffuse lung diseases. Further research is
needed to understand the role of chitotriosidase in the pathogenesis of sarcoidosis and its
involvement in fibrotic remodelling in certain diffuse lung diseases.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Interstitial lung diseases (ILD) are a heterogeneous group of
lung disorders with different clinical courses and pathoge-
netic mechanisms. Among these diseases, the most common
are sarcoidosis (S), idiopathic pulmonary fibrosis (IPF) and
pulmonary fibrosis associated with systemic sclerosis (SSc).
The prognosis of these diseases depends on the different
evolution towards lung fibrosis. IPF is rapidly progressive and
unresponsive to therapy.1,2 This chronic interstitial disorder
is limited to the lungs and involves fibroblast proliferation,
extracellular matrix deposition, tissue remodelling and
fibrotic destruction of the lung. On the other hand,
sarcoidosis is a multisystemic granulomatous disease gen-
erally associated with a good prognosis (although some
patients develop chronic forms, such as pulmonary fibrosis).
The etiopathogenesis of sarcoidosis and IPF are still
unknown, although sarcoidosis is an inflammatory disease
while IPF is secondary to epithelial lung injury.2–5 The
unpredictable clinical courses of these ILD have motivated
research into potential prognostic biomarkers.6–11
Human chitotriosidase (also known as chitinase 1, a family
18 glycosylhydrolase) breaks down colloidal chitin and is
inhibited by the family 18 chitinase inhibitor, allosamidin.12
The newly synthesised 50 kDa enzyme consists of an N-
terminal structure containing the catalytic groove and a C-
terminal chitin-binding domain connected by a short hinge
region.13,14 Although the physiological functions of this
enzyme are still unclear, there is evidence15–17 that
chitotriosidase is a component of innate immunity and
may defend against pathogens containing chitin, such as
fungi, nematodes and insects. Chitotriosidase is considered
a marker of macrophage stimulation, being mainly produced
by chronically activated tissue macrophages.16,18–21 It was
recently reported that leucocytes may also secrete plasma
chitotriosidase under physiological conditions.16,22 In-
creased activity of serum chitotriosidase is reported in
patients with lysosomal storage disorders (Gaucher syn-
drome, fucosidosis, galactosialidosis), beta-thalassemia,
acute Plasmodium falciparum malaria and visceral Leishma-
niasis.23–29 Increased chitotriosidase activity is also reported
in cerebrospinal fluid of patients with multiple sclerosis.25
In the framework of our research into possible biomarkers
of ILD, we reported a statistically significant increase in
chitotriosidase activity in serum of sarcoidosis patients with
respect to serum of controls for the first time in 2004.29 The
enzyme activity in serum was correlated with sarcoidosis
radiographic stages, suggesting potential as a prognostic
marker of sarcoidosis. No such correlation was found forTable 1 The anagraphic features of patients with idiopathic pu
systemic sclerosis (SSc) are reported together with the functional
walking test and systolic pulmonary arterial pressure estimated
Age
(M7SD)
Sex
(M/F)
Smoke
(n.pt./tot.)
CV (%)
(M7SD)
FEV
(M7
FPI (no. 38) 63.3579.67 29/9 7/38 68.6724.75 74.
SSc (no. 20) 55.0579.11 7/13 4/20 73.13730.89 73serum levels of ACE. We then investigated alveolar expres-
sion of chitotriosidase in BAL and its reliability as a potential
biomarker of sarcoidosis severity.30 Chitotriosidase activity
in BAL showed a positive correlation with radiographic
stages, serum levels of ACE and quantitative HRCT score,
especially in patients with progressing sarcoidosis. The
hypothesis that serum chitotriosidase activity may be an
indicator of sarcoidosis severity was further supported by
recent research of ours into its activity in serum of patients
with pulmonary tuberculosis and sarcoidosis. We only found
increased activity of chitotriosidase in serum of sarcoidosis
patients; those of TB patients and controls were similar.31
Other studies are still necessary to determine whether
chitotriosidase could be a useful marker of sarcoidosis
severity.
In order to find out whether chitotriosidase is altered in
other ILD, we assayed its activity in serum and BAL of IPF
and SSc patients. The results were compared with those of
serum and BAL of sarcoidosis patients and healthy subjects.Patients and methods
Subjects and sampling
The study population consisted of 38 IPF patients and 20 SSc
patients (Table 1): 7/38 IPF patients and 4/20 SSc patients
were smokers. None of the patients had ever been treated
with steroids or other immunosuppressants, they were
regularly monitored at our Sarcoidosis and Interstitial Lung
Disease Regional Referral Centre in Siena from onset for at
least 12 months. They had no history of concomitant
pathology. They gave their written informed consent to
the study. IPF was diagnosed according to ATS/ERS interna-
tional criteria.1,2 Diagnosis of SSc was based on clinical–
radiological and immunological findings and histopathologi-
cal features. All patients underwent chest HRCTat onset and
every 12 months, documenting fibrosis ranging from mild to
moderate. The patients enrolled in the study had a
documented history of lung fibrosis secondary to systemic
sclerosis, of at least 18 months. Characteristics of sarcoi-
dosis patients and criteria for differentiating disease
severity are reported in previous papers.29,30 Control
subjects were matched for age and gender, had no history
of asthma or allergy and were not under therapy of any kind.
They had normal lung function parameters and chest X-ray.
They were monitored for 12 months and did not develop any
diseases. Only one control was a smoker. All subjects gave
written informed consent to the study.lmonary fibrosis (IPF) and pulmonary fibrosis associated with
data, PaO2 levels on blood gas analysis, desaturation on 6min
by echocardiogram.
1 (%)
SD)
DLCO (%)
(M7SD)
PaO2
(mmHg)
(M7SD)
Desaturation
(n.pt./tot.)
PAPs
(mmHg)
(M7SD)
13723.82 42.24712.36 64.20712.28 10/38 31.33714.93
.7729.5 43.4738.18 70.01719.57 4/20 36.47722.88
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including single-breath diffusing capacity for carbon mon-
oxide were done in both group of patients (Table 1). Chest
X-rays were performed in the posterior–anterior and lateral
projections and were classified by a single experienced
radiologist. High-resolution computed tomography of the
chest was done and a single experienced reader described
the scans. The following parameters were recorded: age,
sex, BAL differential cell count, BAL lymphocyte phenotype,
lung function test (FVC, FEV1, DLCO, TLC), oxygen desa-
turation during 6min walking test, PaO2 values by blood gas
analysis, pulmonary arterial pressures estimated by echo-
cardiogram (Table 1), radiological impairment by chest X-ray
and chest HRCT. In the group of IPF patients the most
common symptoms at onset were stress-related dyspnoea
and dry cough; dyspnoea and asthenia were the most
common symptoms in the SSc patient group.
Blood samples were always collected in the morning,
after 8-h fasting and samples were stored at 80 1C until
assay. Bronchoalveolar lavage was performed for diagnostic
or clinical purposes with the informed consent of patients.
Samples were obtained by instillation of four aliquots (60ml
each) of saline solution by a fibrobronchoscope (Olympus
IT-10). The first BAL sample was kept separate from the
others and was not used for immunological tests. Sub-samples
were cultured for microbes, fungi and viruses to exclude
infections. Cells were separated by centrifuge and the fluid
fraction was frozen for enzyme assays. Cell differential
counts were performed. Lymphocyte phenotype was analysed
by flow cytometry (Facs-Calibur Becton & Dickinson) using
anti-CD3, CD4 and CD8 monoclonal antibodies (Becton &
Dickinson), as previously described.32Chitotriosidase assay
Chitotriosidase activity was determined by a fluorimetric
method using as substrate 22 mM of 4-methylumbelliferyl-b-
D-NNN-triacetylchitotrioside (Sigma Chemical Co.) in citra-
te–phosphate buffer, pH 5.2. 100 ml of substrate was
incubated for 1 h at 37 1C and the reaction was stopped
with 1.4ml of 0.1M glycine–NaOH buffer, pH 10.8, as
previously described.29–31 Fluorescence was read at 450 nm
on a Perkin-Elmer LS40 fluorimeter (excitation wavelength
365 nm). BAL samples from patients and controls were
not concentrated, each sample was assayed in three
replicates. Serum levels of chitotriosidase were expressed
in nmol/h/ml, while chitotriosidase activity in BAL was
expressed as nmol/h/mg protein. Total protein concentra-
tions in BAL were determined with the Bio-Rad Protein assay,
based on Bradford’s method.33 Inter- and intra-assay
coefficients of variability were, respectively, 3.7% and 1%.Table 2 The total cell number on bronchoalveolar lavage, the
lymphocytes were reported in patients with idiopathic pulmonary
sclerosis (SSc).
n. tot. cell. (M7SD) M (%) (M7SD) L (%) (M
FPI (no. 38) 19.878.235.3719.444.346 50.52726.78 26.947
SSc (no. 20) 16.142.22279.632.389 69.7717.44 21.27Statistical analysis
Data were expressed as mean7standard deviation (M7SD).
Since it was not normally distributed (Shapiro–Wilk normal-
ity test), the Kruskall–Wallis test was applied to compare
significant differences between mean values. Comparisons
between groups were performed by a non-parametric test,
namely Dunn’s multiple comparison test (po0.05). All
variables were cross-correlated using the Spearman R
coefficient of correlation (po0.05). Statistical analysis was
performed using GraphPad Prism Version 4.0 software for
Windows (2005).Results
Anagraphic, clinical, functional features of the groups of IPF
and SSc patients are reported in Table 1 and BAL cell profile
and CD4/CD8 ratio in Table 2.
Figure 1 compares chitotriosidase activity in serum from
IPF (19.9713.57nmol/h/ml) and SSc (12.5673.93nmol/h/ml)
patients with previously published activities31 in serum of 95
sarcoidosis patients (118.67114.4nmol/h/ml) and controls
(10.3972.83nmol/h/ml). As previously described by us and
according to the considerable amount of control data reported
in literature (e.g. 15, 18, 26, 29), chitotriosidase activities
o18nmol/h/ml are assumed to be normal values. Mean
chitotriosidase activities in BAL samples from IPF and
SSc patients (15.79717.25 and 8.9277.36nmol/h/mg,
respectively) were higher than previously reported values30
in stable sarcoidosis patients (2.7971.49nmol/h/mg) and
control subjects (2.0671.36) and those of IPF patients were in
the same range as those measured in patients with progressive
sarcoidosis (17.52713.39nmol/h/mg). SSc patients had values
intermediate between those of progressive sarcoidosis and
controls (Fig. 2).
Serum chitotriosidase activity was significantly lower
(po0.001) in IPF and SSs patients than in sarcoidosis
patients, whereas differences with respect the control
group were not significant. The BAL samples from progres-
sing sarcoidosis patients had chitotriosidase activities
significantly higher than those from stable sarcoidosis
patients and controls (po0.001). Values in IPF patients,
but not SSc patients, were significantly higher than values
measured in controls (po0.05) (Fig. 2).
No differences were found between chitotriosidase
activity in serum and BAL of smokers and non-smokers,
though the number of smokers was too small for statistical
analysis.
Chitotriosidase activities in BAL of SSc patients were
inversely correlated with the total number of BAL cells
(Spearman coefficient of correlation R ¼ 0.806, po0.004)bronchoalveolar lavage cell profile and CD4/CD8 ratio of BAL
fibrosis (IPF) and pulmonary fibrosis associated with systemic
7SD) PMN (%) (M7SD) EOS (%) (M7SD) CD4/CD8 (M7SD)
23.58 15.65718.01 7.578.6 1.771.23
15.03 8.38710.83 472.44 1.3370.93
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inversely related to the percentage of neutrophils in BAL
from IPF patients (R ¼ 0.84, po0.002). A correlation
(R ¼ 0.64, p40.04) was also found between chitotriosidase
activities and lymphocyte percentages in BAL samples from
SSc patients.Discussion
Our results show serum chitotriosidase activities in the
normal range (o18 nmol/h/ml) in patients with IPF and SSc.
Measured activities were six to nine times lower thanFigure 2 Chitotriosidase activity (nmol/h/mg) in bronchoalveo
sarcoidosis, idiopathic pulmonary fibrosis, pulmonary fibrosis ass
represents the minimum value, the second line is the 251 percen
percentile and the fifth line is the maximum value.
Figure 1 Chitotriosidase activity (nmol/h/ml) in serum of
patients with sarcoidosis, idiopathic pulmonary fibrosis, pul-
monary fibrosis associated with systemic sclerosis and controls.
The first line represents the minimum value, the second line is
the 251 percentile, the third line is the mediane, the fourth line
is the 751 percentile and the fifth line is the maximum value.previously reported activities in serum of sarcoidosis
patients. This result strongly supports our hypothesis that
serum chitotriosidase activity could be a potential marker of
sarcoidosis severity due to enhanced activation of macro-
phages during formation of sarcoid granulomas34,35 or to the
potential involvement of agents containing chitin in the
development of the disease; while chitotriosidase levels in
serum do not indicate any involvement of this chitinase in
IPF or SSc.
Interestingly, chitotriosidase activities in BAL showed a
different pattern, being significantly higher in IPF and not
only in sarcoidosis patients than controls (Fig. 2). This result
suggests that the increase in chitotriosidase could be the
expression of high activation of certain macrophage subsets
responsible for remodelling and tissue damage both in S and
IPF at alveolar level. A similar process has been described in
non-alcoholic fatty liver disease.36,37 Overexpression of
chitotriosidase was recently reported to promote progres-
sion of uncomplicated steatosis to hepatic fibrosis.36,37
Involvement of chitotriosidase in fibrogenic and remodelling
processes also seems supported by the results of our
previous studies. In fact, activity of chitotriosidase in BAL
was only significantly higher in patients with progressing
sarcoidosis and radiologically documented interstitial lung
involvement; chitotriosidase activity in serum and BAL only
increased in stage II–III sarcoidosis and was correlated with
the extent and degree of lung damage.30 However, the
increased level of chitotriosidase in BAL of IPF patients is
difficult to explain since chitotriosidase levels were not
elevated in BAL of SSc patients. Different immunological
mechanisms may be involved in lung damage in SSc than in
IPF patients. For example, macrophages are activated by
different stimuli and did not release chitotriosidase in BAL of
these patients. A similar result suggesting that chitotriosi-
dase was not a generic marker, elevated in all conditions
characterised by macrophage activation, was normal activ-
ities of the enzyme in tuberculosis.31 This showed thatlar lavage of patients with stable sarcoidosis, progressing
ociated with systemic sclerosis and controls. The first line
tile, the third line is the mediane, the fourth line is the 751
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granulomatous lung diseases with enhanced macrophage
activation, possibly because other pathogenetic mechanisms
activate different macrophage subsets which do not release
chitotriosidase. The lack of increase in chitotriosidase
recorded in SSc patients may also be due to the limited
number of patients enrolled in the study. A future task will
be to increase the population of SSc patients in order to
confirm this result. As with other markers of sarcoidosis,6
alveolar macrophages involved in inflammatory/fibrotic
processes at alveolar level may have similar activation
patterns in sarcoidosis and IPF (different from that in SSc),
leading to enhanced expression of chitotriosidase activity in
both diseases. This enzyme activity may therefore be
considered a specific expression of enhanced macrophage
activation during lung fibrogenesis and not an aspecific
marker that increases in all pathological conditions char-
acterised by macrophage activation. The recent finding that
chitinases contribute to T-helper-2 inflammation in hu-
mans,38 through an IL-3-dependent mechanism, could
explain chitotriosidase increase at alveolar level in IPF
patients in whom evolution towards chronic disease could
involve type-2 cytokines and mediators.39
Malaguarnera et al.20,21 report an increase in serum levels
of chitinase-1 mRNA after macrophage stimulation with
TNFalpha, IFNgamma and LPS and suggested that this
enzyme may play a role in immune response. They report
that prolactin promoted chitotriosidase gene expression in
human macrophages, while interleukin-10 stimulation
down-regulated chitotriosidase synthesis.21,40 Different sub-
populations of macrophages activated by distinct cytokines
may be involved in the pathogenesis of ILD. They seem to be
characterised by expression of mediators such as CCL18 (and
perhaps chitotriosidase) and could play a role in the
induction of collagen synthesis by fibroblasts.6,41,42
The increase in chitotriosidase activity in sarcoidosis
patients both at alveolar and peripheral levels and in IPF
patients only in BAL could be due to the fact that sarcoidosis
is a multisystemic disorder with generally altered immune
responses,5,43,44 while IPF is an interstitial disorder, limited
to the lungs, with immunological alterations only at alveolar
level.2,45–47
Further studies with a greater number of patients are
needed to define the role of chitotriosidase in the prognosis
of sarcoidosis severity and its involvement in the pathogen-
esis of ILD.Acknowledgements
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